TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications today announced that with its latest installation of CompacT SelecT™, the technology remains the most widely adopted system for automated culture of adherent cell lines in T-flasks, used by major pharmaceutical and biotech companies worldwide.
The CompacT SelecT systems installed in these leading companies offer parallel, aseptic cell culture processing in T75 and T175 flasks at any time of day or night, without scientists having to be present, thus providing a continuous supply of consistent quality cells for use in cell-based screening programmes.
The systems sited have each been tailored with a range of options which allow tasks such as automated cell imaging and analysis, control of culture conditions, media additions and passaging of immortalised, primary cells or stem cells. The cells are being used in applications including high throughput screening, lead optimisation, assay development, target identification and validation, as well as toxicity studies. The stem cell lines are being utilised to support research in therapeutic areas such as oncology and neurology.
Dr Dave Thomas, Product Manager at TAP Biosystems stated: "With the number of automated cell culture technologies increasing, we are pleased that our CompacT SelecT system has become the system of choice in the top pharma and biotech companies. Many of these firms now have multiple systems installed at their North American and European sites and a number are looking to place them in their new Asian drug discovery facilities.”
Thomas added: "The adoption of the CompacT SelecT systems by these leading companies is an excellent endorsement that the technology’s performance capabilities perfectly match their rigorous cell culture demands.“
